月经初潮与儿童多发性硬化疾病进程的关联研究
该研究基于美国儿童多发性硬化中心网络数据库,回顾性分析736例儿童期起病女性多发性硬化患者的初潮前后复发率。调整混杂因素后,围初潮期年复发率为0.65,显著高于初潮后0.43(RR 1.52,95%CI 1.16-1.99,p=0.0049)。作者认为青春期启动可能是疾病活动增加时期,或需考虑调整治疗。
要点
- 围初潮期年复发率0.65,高于初潮后0.43(RR 1.52,95%CI 1.16-1.99,p=0.0049)。
- 与初潮前比,围初潮期复发风险HR 1.78(95%CI 1.17-2.70),初潮后HR 1.67(95%CI 1.12-2.50),p=0.025。
- 口服和输注DMT较未用DMT显著降低复发风险,注射DMT无显著差异。
核心结论
- 青春期启动可能是儿童多发性硬化疾病活动增加的时期,或需考虑调整治疗策略。
- 初潮年龄被用作青春期的替代指标,未来测量性类固醇激素的研究可能提供更多信息。
研究设计与样本
- 回顾性分析美国儿童多发性硬化中心网络数据库中前瞻性随访的儿童期起病女性多发性硬化队列。
- 共纳入736例女性患者,平均起病年龄14.4±2.8岁,平均初潮年龄11.6±1.4岁。
- 围初潮期定义为根据初潮整数年龄估算的初潮日期前后各1年。
- 采用负二项回归和重复测量Cox回归模型评估青春期发育阶段与复发率的关联,并调整种族、体重指数和疾病修正治疗(DMT)。
主要发现
- 736例中,初潮前起病73例,围初潮期起病112例,初潮后起病551例。
- 多发性硬化起病中位时间为初潮后2.8年。
- 随访期间86%的患者暴露于DMT。
- 调整后负二项分析:初潮前年复发率0.43,围初潮期0.65,初潮后0.43;与初潮后相比,初潮前RR 1.00(95%CI 0.70-1.43),围初潮期RR 1.52(95%CI 1.16-1.99),p=0.0049。
- 调整后重复事件Cox回归:与初潮前相比,围初潮期复发风险HR 1.78(95%CI 1.17-2.70),初潮后HR 1.67(95%CI 1.12-2.50),p=0.025。
临床怎么用
- 作者认为青春期启动可能是疾病活动增加的时期,或需考虑调整治疗策略。
- 初潮年龄被用作青春期的替代指标,未来测量性类固醇激素的研究可能提供更多信息。
局限性
- 初潮年龄被用作青春期的替代指标。
- 未来测量性类固醇激素的研究可能提供更多信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Sex steroid hormones have been demonstrated to affect the immune system in multiple sclerosis (MS), and puberty may trigger MS activity. We aimed to evaluate the association between menarche and disease course in pediatric MS through comparison of relapse rates across premenarche, perimenarche, and postmenarche periods. METHODS: This is a retrospective analysis of a prospectively followed female cohort with pediatric-onset MS in the US Network of Pediatric MS Centers database. Perimenarche was considered the period from 1 year before to 1 year after the estimated menarche date based on menarche integer age. Relapses were collected prospectively. Negative binomial and repeated-measures Cox regression models were used to assess the association of pubertal development stage with relapse rate, adjusted for race, body mass index, and disease-modifying therapy (DMT). RESULTS: Of 736 participants (all female; mean onset age 14.4 ± 2.8 years; mean menarche age 11.6 ± 1.4 years), onset was in premenarche in 73, perimenarche in 112 (± 1 year of menarche), and postmenarche in 551. The median time of MS onset was 2.8 years after menarche. Most (86%) were exposed to DMT in follow-up. In adjusted negative binomial analysis, the annualized relapse rate during premenarche was 0.43, perimenarche was 0.65, and postmenarche was 0.43 (premenarche rate ratio [RR] 1.00 (95% CI 0.70-1.43) and perimenarche RR 1.52 (95% CI 1.16-1.99), compared with reference of postmenarche, p = 0.0049. In adjusted repeated-events Cox regression analysis, there was increased hazard to relapse in perimenarche and postmenarche compared with premenarche (perimenarche hazard ratio [HR] 1.78 [95% CI 1.17-2.70] and postmenarche HR 1.67 [95% CI 1.12-2.50], compared with reference of premenarche, p = 0.025). In this analysis, use of oral and infusion DMTs significantly lowered the relapse hazard compared with periods of no DMT use (injectable HR 0.98 [95% CI 0.83-1.15], oral HR 0.48 [95% CI 0.37-0.61], and infusion HR 0.24 [95% CI 0.18-0.31], compared with no DMT, p < 0.001). DISCUSSION: Onset of puberty may be a time of increase in disease activity and may require consideration of a change in therapeutic approach. Menarche age was used as a surrogate for puberty, and future studies measuring sex steroid hormones may be informative.
引用
- Krysko KM, Waltz M, Chitnis T, et al. Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis. Neurology. 2025. PMID: 39899789. doi:10.1212/WNL.0000000000210213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。